PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2092774
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2092774
Dural Adhesive Agent For Surgical market size was valued at US$ 210.8 Million in 2025, expanding at a CAGR of 5.6% from 2026 to 2033.
Dural adhesive means that biocompatible adhesives are mainly used for the purpose of creating an airtight seal on the dura mater during neurosurgery and spine surgery so that there is no leakage of cerebrospinal fluid and also help in the healing of the tissues. The major ingredients of the adhesive include a dual-chambered syringe that contains synthetic polymer precursors such as polyethylene glycol along with the initiation agent for cross-linking, which, when mixed together, forms a hydrogel patch. This ensures reliable dural sealing, minimizes postoperative complications, and supports improved surgical recovery outcomes.
Dural Adhesive Agent For Surgical Market- Market Dynamics
Rising Number of Neurosurgical Procedures to Propel Market Demand
The growth of the number of neurosurgeries is anticipated to enhance the demand for the dural adhesive agents for the surgical market because of the increased need for efficient dural closure during cranial and spinal surgeries. Effective dural adhesion ensures that there is less leakage of cerebrospinal fluid, effective sealing of the tissues, and enhanced postoperative recovery and surgical outcome. For instance, according to the 2025 study published in PubMed Central (PMC), there has been an increase of 301, which is 210.3%, in the number of neurosurgeons from 97, whereas there was an increase of 28.6% in inpatient neurosurgical stays. There has been a 0.1% increase in cranial surgeries, which shows the increase in the demand for specialized neurological surgeries, thereby raising the number of neurosurgeries across the globe. thus indicating the rise in the demand for specialized neurological surgeries and an increase in the number of neurosurgeries worldwide.
The Global Dural Adhesive Agent For Surgical market is segmented on the basis of Product Type, Application, Form, and Region.
Based on product type, the polyethylene glycol segment holds a notable share in the Dural Adhesive Agent For Surgical market because of its superior biocompatibility, high level of sealing, and popularity among neurosurgeries to prevent cerebrospinal fluid leakage. According to NIH Gov (Polyethylene Glycol), in a double-blind, placebo-controlled study of 6 months on 70 patients suffering from chronic constipation, polyethylene glycol electrolyte solution therapy showed a 77% complete relief of constipation symptoms, compared to 20% in the placebo arm, without any significant differences in the safety profiles of both groups. This research further highlights the utility of polyethylene glycol as a therapy for chronic constipation.
In terms of application, the spinal surgery segment is likely to exhibit notable growth in dural adhesive agents for the surgical market because of the rising volume of spinal surgeries along with the growing requirement for efficient dural sealants to prevent any post-surgical complications. For example, as stated in the research study conducted at the National Library of Medicine (PMC), the number of spinal surgery claims recorded in the New York metropolitan area rose from 26,066 surgeries to 30,485 surgeries, which is about a 17% increase as compared to pre-COVID-19 levels. Furthermore, it was also found in the report that spinal surgery numbers recovered after the COVID-19 disruption and surpassed pre-COVID-19 levels due to the increasing prevalence of degenerative spine disease, which constituted 79.5% of all spinal surgeries. This accelerating procedural growth is expected to drive sustained demand for advanced dural adhesive agents.
Dural Adhesive Agent For Surgical Market- Geographical Insights
North America is expected to account for a significant share of the dural adhesive agent for the surgical market because of the highly developed healthcare sector, the presence of major companies, and regular R&D activities. For instance, according to the ISPOR US Healthcare System Overview, the United States provides healthcare services to more than 330 million people through one of the most complex and developed healthcare systems in the world. The country spends close to USD 4,300,000 million on healthcare, accounting for 18.3% of its GDP. It consists of networks of government and privately owned hospitals, highly developed infrastructure for healthcare service provision, specialists in healthcare services provision, and a comprehensive reimbursement system. Thus, the increased number of spine surgeries will definitely drive up demand for dural adhesives.
India Dural Adhesive Agent For Surgical Market- Country Insights
India has experienced consistent growth in medical tourism, as there has been a substantial rise in the number of foreign patients visiting the country in search of medical care. For instance, in 2026, according to the Press Information Bureau (PIB), Government of India, the number of international visitors increased to 644,387 from 182,945, registering an increase of more than 252% in just four years. Such steady growth in medical tourism in India is attributed to India's growing medical value travel ecosystem, advanced healthcare infrastructure, low costs of treatment, government efforts like the "Heal in India" campaign, and the rising demand worldwide for combined medical and wellness solutions. This growth continues to strengthen India's global leadership in high-quality, affordable medical tourism services.
Competition in the Dural Adhesive Agent For Surgical market is driven by leading companies such as Stryker, DuraStat, Inc., Covidien (Medtronic), Becton, and Regenity. These companies are focused on developing advanced dural sealants with improved biocompatibility, stronger sealing performance, and enhanced surgical outcomes. In May 2025 Stryker launched the OptaBlate(R) BVN Basivertebral Nerve Ablation System following FDA 510(k) clearance, expanding its interventional spine and neurosurgical portfolio with advanced minimally invasive technology that strengthens its position in surgical tissue management and related specialties. These strategic advancements reinforce competitive positioning while driving innovation and improving surgical treatment outcomes.
In February 2026 Regenity Biosciences received a strategic investment from Cinven, forming a partnership alongside Linden Capital Partners to accelerate innovation, manufacturing expansion, and commercialization of regenerative medical devices, including neurosurgical biomaterial technologies.